A phase II study assessing tumor blood flow as measured by dynamic contrast enhanced MRI [magnetic resonance imaging] in patients with metastatic colorectal cancer receiving FOLFOX [calcium folinate + fluorouracil + oxaliplatin] alone versus patients randomized to receive FOLFOX plus bevacizumab at 5mg/kg or 10mg/kg.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 25 Feb 2008 New trial record.